Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that used to be recommended to prevent influenza. In June 2016 the CDC stopped recommending the use of LAIV as its effectiveness has appeared to have decreased between 2013 and 2016.
It is an attenuated vaccine, unlike most influenza vaccines, which are inactivated vaccines. LAIV is administered intranasally, while inactivated vaccines are administered by intramuscular injection. Both live attenuated and inactivated vaccines are typically trivalent. That is, they contain material from three different influenza virus strains recommended by national and international public health agencies as most likely to be protective against seasonal influenza in any given year. LAIV is sold under the trade name FluMist in the United States and Canada, and Fluenz in Europe. FluMist is manufactured by MedImmune and was first introduced in 2003.
Video Live attenuated influenza vaccine
Medication uses
In 2016 the CDC recommended that LAIV not be used for the 2016-2017 flu season and instead another type of influenza vaccine be used. This is due to the poor effectiveness of this type of vaccine between 2013 and 2016 with it being non effective during the 2015-2016 season. A 2012 review found that LAIV prevents influenza in about one out of six children under six it is given to. It was believed to prevent about 50% more cases of flu than the flu shot in younger children. In those less than 2 years old evidence the evidence was however unclear. Why there appears to be a decrease in effectiveness is unknown.
Not recommended
- children <24 months of age, due to increased risk of wheezing
- individuals with a history of hypersensitivity to previous influenza vaccination.
- individuals with a history of hypersensitivity, especially anaphylactic reactions, to eggs, egg proteins, gentamicin, gelatin, or arginine or to any other ingredient in the formulation
- People with a medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease
- People with medical conditions such as diabetes or kidney failure or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system
- Children less than 5 years old with a history of recurrent wheezing
- Children or adolescents receiving aspirin
- People with a history of Guillain-Barré syndrome, a rare disorder of the nervous system
- Pregnant women
- People who have a severe allergy to chicken eggs or who are allergic to any of the nasal spray vaccine components
It is possible for individuals vaccinated with FluMist to spread the virus to others for up to 21 days after vaccination. For this reason it is recommended that those vaccinated with FluMist avoid close contact with individuals with weak immune systems during that time.
Maps Live attenuated influenza vaccine
Risks
Even though the virus in LAIV is attenuated (low in virulence), it is still a living virus, and may cause an infection with complications in people with weakened immune systems or other underlying medical conditions. As of 2010, LAIV is recommended only for people 2-49 years of age, and is not recommended for people who have a weakened immune system, for pregnant women, or for people with certain chronic diseases. In contrast, inactivated virus vaccines contain no living virus, and cannot cause a live infection. Persons receiving LAIV may shed small amounts of the vaccine virus during the first week. People coming in contact with the vaccinated person are not considered to be at risk, unless their immune systems are severely weakened (for example, bone marrow transplant recipients).
History
FluMist was originally developed by Hunein "John" Maassab, Professor of Epidemiology at the University of Michigan School of Public Health in Ann Arbor, Michigan and later by Aviron, in Mountain View, California, under the sponsorship of NIH in the mid-1990s. MedImmune, Inc. purchased Aviron in 2002, and the FDA approved FluMist in June 2003. FluMist was first made available in September 2003.
The U.S. FDA initially approved FluMist only for healthy people ages 5 to 49 because of concerns over possible side effects. Now FluMist is approved and recommended for healthy children 24 months of age and older. The FDA approved the current unfrozen refrigerated version for the same age group (ages 5-49) in August 2006 following completion of phase 3 clinical trials. CAIV-T has been approved by the FDA and is the version offered on the market beginning in fall of 2007.
The current version of the vaccine is called CAIV-T, and is stable for storage in a refrigerator, rather than requiring freezer storage as did the originally-approved formulation. Approved for the 2007-2008 flu season, the refrigerated formulation can be distributed more economically, so that the price differential with shots (which had hampered sales of the original frozen version of FluMist) is now largely eliminated. FluMist was initially priced higher than the injectable vaccines, but sold only 500,000 of the 4 million doses it produced its first year on the market, despite a comparative shortage of flu vaccine in fall 2004. The price was sharply lowered the next year, and the company reports distributing 1.6 million doses in 2005. Because of the price drop, despite selling almost three times as many doses in 2005, the company reported $21 million in FluMist sales, compared to $48 million the previous year. Further cuts in pricing had to await FDA approval of a refrigerator-cooled FluMist formulation, as the initial formulation required freezer storage and thawing on demand before administration. Although it is positioned as a premium product, the remaining price premium for FluMist over the cost of needle-injected vaccine is small.
The FDA's regulatory pathway for FluMist has been suggested as a possible precedent for phage therapy.
Society and culture
MedImmune is one company that manufactures LAIV, which it sells under the trade name "FluMist" in the United States and "Fluenz" in Europe. For the 2010-2011 flu season, FluMist was the only LAIV approved by the FDA for use in the USA. All other FDA-approved lots were inactivated virus vaccines. In September 2009 a LAIV intranasal vaccine for the novel H1N1 influenza virus was approved and the seasonal intranasal vaccine was approved by the European Medicines Agency for use in the European Union in 2011, though distribution would not likely begin until 2012.
As of 2007, the only other company holding LAIV vaccine rights was BioDiem of Australia. BioDiem licensed rights to private production of the vaccine in China to Changchun BCHT Biotechnology, which also holds public rights for production in China sublicensed from the World Health Organization. BCHT plans to market a trivalent LAIV vaccine for H1N1 flu by the end of 2016. The BCHT flu vaccine is one of several candidates for WHO prequalification in the near future, reflecting a shift of Chinese market priorities from a large domestic market toward export. BioDiem has also licensed production to the Serum Institute of India, which holds exclusive licenses for production in Mexico, Argentina, Peru, South Africa, Bangladesh, Bhutan, Nepal, Pakistan and Sri Lanka, and the Government Pharmaceutical Office of Thailand. It was the first and (as of 2007) the only live attenuated vaccine for influenza available outside of Europe. In September 2009 a LAIV intranasal vaccine for the novel H1N1 influenza virus was approved. In 2011, the vaccine was approved by the European Medicines Agency for use in the European Union under the name Fluenz.
Research
FluMist is designed to be quickly modifiable to present the surface antigens of seasonal flu. The modifiability could also allow it to be quickly customized as a vaccine against a pandemic influenza if one were to emerge. In light of the Global spread of H5N1 advance preparation to reduce human mortality in the event of an H5N1 pandemic has begun. Modifying FluMist to serve as a specific human H5N1 vaccine is among the measures studied.
In June 2006, the National Institutes of Health (NIH) began enrolling participants in a Phase 1 H5N1 study of an intranasal influenza vaccine candidate based on MedImmune's live, attenuated vaccine technology.
In September 2006 the NIH NIAID reported that inoculation with a FluMist vaccine modified to present the surface antigens of certain H5N1 variants provided broad protection against other H5N1 variants in the mouse and ferret models. Attenuated live viruses were found protective against H5N1 in mice and chickens in a 2009 study.
Although early work is focusing on the looming H5N1 threat, the CDC team led by Kanta Subbarao and others intends to eventually prepare and store surface antigens for all known strains of influenza, ready to be grafted onto the base attenuated FluMist core virus whenever a pandemic threat might emerge.
"Several trials have reported that LAIVs can boost virus-specific CTLs as well as mucosal and serum antibodies and provide broad cross-protection against heterologous human influenza A viruses." (58, 59) "[V]accine formulas inducing heterosubtypic T cell-mediated immunity may confer broad protection against avian and human influenza A viruses."
In September 2009 a LAIV intranasal vaccine for the novel H1N1 influenza virus was approved.
References
External links
- FluMist nasal flu vaccine - Official website
- FluMist information on University of Michigan, School of Public Health website
- Live Attenuated Vaccine in Russia presentation on Russian live influenza vaccines since 1961
- CDC Vaccine Information Statement Live, Attenuated Influenza Vaccine
- CDC Vaccine Information Statement 2009 H1N1 LAIV
- Summary of the European public assessment report (EPAR) for Fluenz
- FDA prescribing information
Source of the article : Wikipedia
0 Comments